

John S Bradley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4232289/publications.pdf>

Version: 2024-02-01

67
papers

3,228
citations

186209

28
h-index

155592

55
g-index

67
all docs

67
docs citations

67
times ranked

3899
citing authors

#	ARTICLE	IF	CITATIONS
1	Spectrum of Viral Pathogens Identified in Children with Clinical Myocarditis (Pre-Coronavirus) Tj ETQq1 1 0.784314 rgBT /Overlock 10 18-24.	0.9	6
2	Selective Valve Removal for Melody Valve Endocarditis: Practice Variations in a Multicenter Experience. <i>Pediatric Cardiology</i> , 2022, 43, 894-902.	0.6	2
3	Key clinical research priorities for the pediatric community during the COVID-19 pandemic. <i>Pediatric Research</i> , 2021, 89, 730-732.	1.1	4
4	Detection of <i>Neisseria gonorrhoeae</i> from Joint Aspirate by Metagenomic Sequencing in Disseminated Gonococcal Infection. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 367-369.	0.6	6
5	Antimicrobial prescribing for treatment of serious infections caused by <i>Staphylococcus aureus</i> and methicillin-resistant <i>Staphylococcus aureus</i> in pediatrics: an expert review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1107-1116.	2.0	5
6	Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 801-844.	0.6	96
7	Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 238-244.	1.1	8
8	Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 814-823.	1.1	16
9	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 835-864.	0.5	640
10	Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population. <i>American Journal of Perinatology</i> , 2020, 38, 804-809.	0.6	8
11	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2020, 40, 363-367.	1.2	56
12	Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2020, 47, 199-218.	0.8	6
13	176. Selected Impact of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) at Eight Children's Hospitals in the United States. 2014-2019. <i>Open Forum Infectious Diseases</i> , 2020, 7, S216-S217.	0.4	3
14	Two cases of type-a <i>Haemophilus influenzae</i> meningitis within the same week in the same hospital are phylogenetically unrelated but recently exchanged capsule genes. <i>Microbial Genomics</i> , 2020, 6, .	1.0	3
15	Invasive Pneumococcal Disease in Children's Hospitals: 2014-2017. <i>Pediatrics</i> , 2019, 144, .	1.0	32
16	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. <i>Clinical Infectious Diseases</i> , 2019, 68, 895-902.	2.9	251
17	Community-acquired pneumonia in children: cell-free plasma sequencing for diagnosis and management. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 188-191.	0.8	51
18	2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children. <i>Open Forum Infectious Diseases</i> , 2019, 6, S952-S952.	0.4	0

#	ARTICLE	IF	CITATIONS
19	471. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate (TZD) in Adolescents with Acute Bacterial Skin and Skin Structure Tissue Infections (ABSSSI). <i>Open Forum Infectious Diseases</i> , 2019, 6, S230-S231.	0.4	0
20	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. <i>Clinical Infectious Diseases</i> , 2019, 68, e1-e47.	2.9	449
21	Advancing Pediatric Antibacterial Drug Development: A Critical Need to Reinvent our Approach. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2019, 8, 60-62.	0.6	4
22	Perceived barriers to pediatrician and family practitioner participation in pediatric clinical trials: Findings from the Clinical Trials Transformation Initiative. <i>Contemporary Clinical Trials Communications</i> , 2018, 9, 7-12.	0.5	14
23	Parents' perceived obstacles to pediatric clinical trial participation: Findings from the clinical trials transformation initiative. <i>Contemporary Clinical Trials Communications</i> , 2018, 9, 33-39.	0.5	62
24	Antiviral treatment of childhood influenza: an update. <i>Current Opinion in Pediatrics</i> , 2018, 30, 438-447.	1.0	13
25	Invasive Pneumococcal Disease in Infants Aged 0-60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 249-252.	0.6	6
26	Multimodal Treatment of Rhinocerebral Mucormycosis in a Pediatric Patient With Relapsed Pre-B Acute Lymphoblastic Leukemia. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 555-558.	1.1	8
27	Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S108-S122.	1.0	37
28	Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children With Proven or Suspected Gram-Negative Infection. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1130-1136.	1.1	29
29	Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 893-900.	1.1	37
30	Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	5
31	Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing. <i>Pharmacotherapy</i> , 2017, 37, 361-378.	1.2	26
32	Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era. <i>Clinical Infectious Diseases</i> , 2017, 64, 1699-1704.	2.9	85
33	Invasive pneumococcal infections in children following transplantation in the pneumococcal conjugate vaccine era. <i>Transplant Infectious Disease</i> , 2017, 19, e12630.	0.7	24
34	Extensive orf infection in a toddler with associated id reaction. <i>Pediatric Dermatology</i> , 2017, 34, e337-e340.	0.5	9
35	Intravenous Zanamivir in Hospitalized Patients With Influenza. <i>Pediatrics</i> , 2017, 140, .	1.0	29
36	Pharmacokinetics of single-dose ceftaroline fosamil in children with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, 1424-1434.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Emergence of Multidrug-Resistant Pneumococcal Serotype 35B among Children in the United States. <i>Journal of Clinical Microbiology</i> , 2017, 55, 724-734.	1.8	74
38	Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-acquired Bacterial Pneumonia. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 345-355.	1.0	27
39	Augmented Renal Clearance Using Vancomycin Population-Based Pharmacokinetic Modeling With Bayesian Estimation in Critically-Ill Pediatric Patients. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
40	Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Zanamivir (IVZ) Treatment in Hospitalized Pediatric and Adolescent Patients with Influenza: A Phase II Open-Label, Multicenter, Single-Arm Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
41	Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 813-815.	1.1	16
42	Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e178-e189.	4.6	14
43	Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2150-2156.	1.4	37
44	Pneumococcal Invasive Disease in Infants Younger Than 60 Days in the United States in the 13-Valent Pneumococcal Conjugate Vaccine Era. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
45	A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 752-759.	1.1	54
46	A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e239-e247.	1.1	47
47	Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 628-633.	1.1	25
48	Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 748-752.	1.1	41
49	Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. <i>Clinical Infectious Diseases</i> , 2015, 61, 767-775.	2.9	115
50	Pharmacodynamic Characteristics of Nephrotoxicity Associated With Vancomycin Use in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e109-e116.	0.6	82
51	Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4742-4749.	1.4	8
52	Bayesian Estimation of Vancomycin Pharmacokinetics in Obese Children: Matched Case-Control Study. <i>Clinical Therapeutics</i> , 2015, 37, 1340-1351.	1.1	24
53	Multicenter Surveillance of <i>Streptococcus pneumoniae</i> Isolates From Middle Ear and Mastoid Cultures in the 13-Valent Pneumococcal Conjugate Vaccine Era. <i>Clinical Infectious Diseases</i> , 2015, 60, 1339-45.	2.9	45
54	Osteoarticular Infections in Children. <i>Infectious Disease Clinics of North America</i> , 2015, 29, 557-574.	1.9	126

#	ARTICLE	IF	CITATIONS
55	78Pneumococcal Meningitis among 8 Children's Hospitals in the United States in the 13-valent Pneumococcal Conjugate Vaccine Era. <i>Open Forum Infectious Diseases</i> , 2014, 1, S2-S3.	0.4	0
56	958Streptococcus pneumoniae Serotype 3 Invasive Infections in Children. <i>Open Forum Infectious Diseases</i> , 2014, 1, S278-S279.	0.4	0
57	77Continued Decline in Invasive Pneumococcal Infections in Children Among 8 Children's Hospitals in the United States 2011 to 2013. <i>Open Forum Infectious Diseases</i> , 2014, 1, S2-S2.	0.4	1
58	Single-dose Pharmacokinetics of Daptomycin in Pediatric Patients 3â€“24 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 936-939.	1.1	30
59	Which antibiotic for resistant Gram-positives, and why?. <i>Journal of Infection</i> , 2014, 68, S63-S75.	1.7	22
60	Characteristics of Severe Bordetella pertussis Infection Among Infants <=90 Days of Age Admitted to Pediatric Intensive Care Units - Southern California, September 2009-June 2011. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 1-6.	0.6	62
61	Prevalence of Hepatitis C Virus Antibody in Newborn Infants in Southern California in 2003. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 618-620.	1.1	4
62	Considerations Unique to Pediatrics for Clinical Trial Design in Hospitalâ€“Acquired Pneumonia and Ventilatorâ€“Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2010, 51, S136-S143.	2.9	29
63	Intravenous Ceftriaxone and Calcium in the Neonate: Assessing the Risk for Cardiopulmonary Adverse Events. <i>Pediatrics</i> , 2009, 123, e609-e613.	1.0	120
64	Unique Considerations in the Evaluation of Antibacterials in Clinical Trials for Pediatric Communityâ€“Acquired Pneumonia. <i>Clinical Infectious Diseases</i> , 2008, 47, S241-S248.	2.9	22
65	Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 794-799.	1.1	79
66	Comparative Study of Levofloxacin in the Treatment of Children With Community-Acquired Pneumonia. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 868-878.	1.1	73
67	Old and new antibiotics for pediatric pneumonia. <i>Seminars in Respiratory Infections</i> , 2002, 17, 57-64.	1.3	5